F3

Step One Automotive Group Invites Community to Attend HSU Educational Foundation Presentation With FIA Formula 3 Driver Juan Manuel Correa

Retrieved on: 
Donnerstag, Oktober 21, 2021
Emerald, ART Grand Prix, Bommarito Automotive Group 500, Goal, Happiness, Special Forces Group, ART, Partnership, F3, Francorchamps, FIA, JM, Florida, Awareness, Police, F2, Emerald Coast, Employment, GLOBE, Robotics

JM Correa is an American-Ecuadorian racing driver who grew up in Miami and currently competes with ART Grand Prix in FIA Formula 3.

Key Points: 
  • JM Correa is an American-Ecuadorian racing driver who grew up in Miami and currently competes with ART Grand Prix in FIA Formula 3.
  • Having suffered a tragic and almost career-ending accident in August 2019 racing in F2 Championship at Spa Circuit in Belgium, JM returned to Europe this year to compete in the 2021 FIA Formula 3 Championship.
  • Those same characteristics are the reason why JM is now inspiring many with one of the most incredible comebacks in motorsport history.
  • Correa will be visiting the Emerald Coast as part of a partnership with racing sponsor Step One Automotive Group starting Monday, Oct.25,through Thursday, Oct. 28, 2021.

Worldwide At-Home Fitness Equipment Industry to 2027 - Featuring Tonal Systems, Technogym and Louis Vuitton Among Others - ResearchAndMarkets.com

Retrieved on: 
Montag, Oktober 11, 2021
Online Retail, Retail, Health, Department Stores, Fitness & Nutrition, Specialty, CAGR, Adoption, Prevalence, Heart rate, Government, Growth, Urban, Industry, Life Fitness, Obesity, Population, F3, Arm, Plumbing, Retail

The global at-home fitness equipment market was valued at $5,545 million in 2019, and is projected to reach $11,459 million by 2027, registering a CAGR of 7.8% from 2021 to 2027.

Key Points: 
  • The global at-home fitness equipment market was valued at $5,545 million in 2019, and is projected to reach $11,459 million by 2027, registering a CAGR of 7.8% from 2021 to 2027.
  • The most commonly used at-home fitness equipment include treadmills, stationary cycles, free weights, elliptical and others.
  • Increase in prevalence of obesity and rise in health consciousness have majorly boosted the growth of the global at-home fitness equipment market.
  • Depending on product type, the at-home fitness equipment market is categorized into cardiovascular training equipment, free weights, and power racks.

Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program

Retrieved on: 
Montag, September 13, 2021
Precision medicine, Risk, U.S. Securities and Exchange Commission, Security (finance), Biomarker, Government, Transcriptome, AI, HCV, Cyclophilin, FDA, Drug development, Efficiency, Ill, Cirrhosis, HBV, Liver disease, Pharmacology, F2, Failure, Doctor of Philosophy, Doctor of Pharmacy, NASH, HEPA, AASLD, Patient, Company, HDV, Private Securities Litigation Reform Act, Gene, Genomics, Gene expression, Lipidomics, III, Safety, Machine learning, NASDAQ, Fatty liver disease, Pharmacokinetics, ALT, COVID-19, RNA, Mayo, Webcast, Observation, GLOBE, Artificial intelligence, Response, Proteomics, Metabolomics, F3, Pharmaceutical industry, Medical imaging, Medical device

AMBITION, a multicenter, randomized, placebo controlled, single-blind Phase 2a trial, enrolled 43 NASH patients.

Key Points: 
  • AMBITION, a multicenter, randomized, placebo controlled, single-blind Phase 2a trial, enrolled 43 NASH patients.
  • As previously reported , all primary endpoints of the AMBITION NASH trial (safety, tolerability and pharmacokinetics) were met.
  • Importantly, more detailed analyses of the AMBITION trial data using Hepions proprietary AI-POWR platform provided further evidence of CRV431 efficacy in the treatment of NASH.
  • ET, during which both the Phase 2a AMBITION trial data and the design of the planned Phase 2b ASCEND-NASH trial will be discussed.

High Performance, Closed-Loop Piezo Controller with Integrated Piezo Driver / Amplifier for Precision Motion Control and Nanopositioning

Retrieved on: 
Mittwoch, August 18, 2021
MetaMorph, Microsoft Windows, PI, OEM, Nano, F3, Wide-field multiphoton microscopy, Digital, USB, Family, 3D reconstruction, Research, Transducer, Semiconductor, Shapeshifting, Wave, Mechanism, Motion, Safety, Temperature, LabVIEW, Direct digital control, SPI, Bear spray, Linux, MATLAB, Electronic component

Digital Controller with Fast Focus and Freeze, Automated Scans, Software Support

Key Points: 
  • Digital Controller with Fast Focus and Freeze, Automated Scans, Software Support
    The new E-709 compact digital piezo servo controller / amplifier and driver was designed providing 20kHz sampling rate, twice the power of its predecessor along with multiple times is positioning resolution.
  • This feature allows for calibrated, precise, and highly stable motions on a nanometer scale, with respect to the focal plane.
  • The new E-709 compact digital piezo controller is supported by a comprehensive software package including drivers for LabVIEW, dynamic libraries for Windows and Linux, MATLAB, MetaMorph, Manager, etc.
  • Several application parameters should be considered when selecting the right closed-loop piezo controller for a specific nanopositioning or high-speed precision motion task.

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Freitag, August 13, 2021
Trial of the century, Inflammation, U.S. Securities and Exchange Commission, Clinical trial, Fatty liver disease, F4, Research, SAN, FGF21, F2, Liver failure, Risk, Private Securities Litigation Reform Act, Disease, F3, COVID-19, Therapy, GLOBE, Nature Medicine, NASH, SEC, GMP, EFX, Annual report, Patient, Security (finance), Fibrosis, Metabolism, API, Safety, Cirrhosis, Liver injury, Pharmaceutical industry, Risk management

(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021.

Key Points: 
  • (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021.
  • During the second quarter, Akero continued to enroll patients in the HARMONY study, a Phase 2b multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed pre-cirrhotic NASH patients (fibrosis stages F2 and F3).
  • During the second quarter, Akero successfully initiated GMP manufacture of drug substance (API) to be used for Phase 3 evaluation of EFX.
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.

NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Donnerstag, August 5, 2021
Protein-bound paclitaxel, Human, F2, Biology, NGM, Part, Board, Cancer, Drug discovery, Pembrolizumab, Safety, Roger M. Perlmutter, Retina, Lists of diseases, Amgen, Private Securities Litigation Reform Act, AST, Ophthalmology, ESMO, Nash, Oncology, European Society for Medical Oncology, Therapy, Multiple comparisons problem, Cirrhosis, Fibrosis, Leadership, F3, SEC, Injection, Failure, Board of directors, GLOBE, Research, CVM, U.S. Securities and Exchange Commission, Trial of the century, IVT, Patient, COVID-19, Alt, FAF, Geographic atrophy, Risk, Nasdaq, Liver, Pharmaceutical industry, Medical imaging, Cryptocurrency, Fine chemical

NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.

Key Points: 
  • NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.
  • NGM reported a net loss of $36.7million for the quarter ended June30, 2021, compared to a net loss of $25.6 million for the same period in 2020.
  • R&D expenses were $43.6million for the quarter ended June30, 2021, compared to $38.5million for the same period in 2020.
  • General and administrative expenses were $9.8million for the quarter ended June30, 2021, compared to $6.8million for the same period in 2020.

Four Female Founders (F3) Support Girls Being Born Worthy

Retrieved on: 
Dienstag, Juni 19, 2018
Childhood, Girl, Women, F3, Stephanie

Merlino explained, "Through Born Worthy, girls and their families are given the tools to counteract the conscious and unconscious forces that make our daughters feel unsafe, insecure and not good enough."

Key Points: 
  • Merlino explained, "Through Born Worthy, girls and their families are given the tools to counteract the conscious and unconscious forces that make our daughters feel unsafe, insecure and not good enough."
  • Born Worthy, a not for profit organization dedicated to preparing girls to successfully navigate young womanhood, is one of the initiatives being funded by Julie Fogg's Four Female Founders (F3).
  • Stephanie went on to say, "The dreams of young girls need to be encouraged and validated."
  • Active Port is the proud inaugural sponsor of the Four Female Founders (F3) initiative and SparkiCreative sponsored the event logistics.

Four Female Founders (F3): A New Promise to Women

Retrieved on: 
Montag, Juni 11, 2018
Nell Merlino, F3

LONG BEACH, Calif., June 11, 2018 /PRNewswire-PRWeb/ -- FOUR FEMALE FOUNDERS (F3), is a proof of concept program committed to building up women in various organizations.

Key Points: 
  • LONG BEACH, Calif., June 11, 2018 /PRNewswire-PRWeb/ -- FOUR FEMALE FOUNDERS (F3), is a proof of concept program committed to building up women in various organizations.
  • "However, what is a historically persistent problem is that women continue to make less money than men for equal work and female founders receive less than 10% of all investment dollars in their companies.
  • That is why I am thrilled to be a part of Four Female Founders (F3)," added Merlino, who will deliver the keynote address.
  • For Julie, FOUR FEMALE FOUNDERS (F3) is a passing of the torch from Nell Merlino to Julie.